

# CONTENTS

<u>Chapter No.</u>	<u>Title</u>	<u>Page No.</u>
	LIST OF FIGURES .....	v
	LIST OF TABLES .....	vii
	SUMMARY .....	viii
	ACKNOWLEDGMENTS .....	xi
	ABBREVIATIONS AND SYMBOLS .....	xii
1.	INTRODUCTION.....	1—5
2.	REVIEW OF LITERATURE.....	6—27
2.1	AN INTRODUCTION TO STEM CELLS.....	6
2.2	Stem Cells.....	6
2.3	Types of Stem Cells.....	6
2.3.1	<i>Embryonic Stem Cells</i> .....	6
2.3.2	<i>Adult Stem Cells</i> .....	7
2.4	Bone Marrow.....	7
2.4.1	<i>Hematopoietic Stem Cells</i> .....	7
2.4.2	<i>Mesenchymal Stem Cells</i> .....	7
2.4.3	<i>Endothelial Progenitor Cells</i> .....	8
2.4.4	<i>Multipotent Adult Progenitor Cells</i> .....	8
2.5	CARDIOVASCULAR SYSTEM.....	9
2.5.1	<i>Heart</i> .....	9

2.5.2	<i>Microstructure of the Heart</i> .....	10
2.5.3	<i>Blood Circulation</i> .....	12
2.6	CARDIOVASCULAR DISEASES.....	13
2.6.1	<i>Diabetes and Cardiovascular Diseases</i> .....	14
2.6.2	<i>Diabetic Cardiomyopathy</i> .....	15
2.7	TREATMENT AND MANAGEMENT OF DCM.....	19
2.7.1	<i>Life Style</i> .....	19
2.7.2	<i>Glycemic Control</i> .....	19
2.7.3	<i>Dyslipidemia Treatment</i> .....	19
2.7.4	<i>Antihypertensive Treatment</i> .....	20
2.8	SOME ADDITIONAL THERAPEUTIC STRATEGIES.....	20
2.8.1	<i>Apelin and Cardiac Output</i> .....	20
2.8.2	<i>Kinins</i> .....	20
2.8.3	<i>Sarcoplasmic Reticulum Calcium ATPase (SERCA2)</i> ..	21
2.8.4	<i>Antioxidants</i> .....	21
2.8.5	<i>Erythropoietin</i> .....	22
2.8.6	<i>Cellular Therapy</i> .....	25
2.8.7	<i>Combining MSCs Transplanatation and EPO Treatment</i>	26
3.	MATERIALS AND METHODS	28—38
3.1	Animals.....	28
3.2	Mouse Model for Diabetes.....	28
3.3	<i>In vitro</i> Study.....	28

3.3.1	<i>Cell Culture</i> .....	28
3.3.2	<i>Flow Cytometry</i> .....	28
3.3.2	<i>Preconditioning of Diabetic MSCs</i> .....	29
3.3.3	<i>Gene Expression Profiling of MSCs</i> .....	29
3.3.4	<i>Hypoxic Stress</i> .....	31
3.3.5	<i>Superoxide Dismutase Assay</i> .....	32
3.3.6	<i>Apoptosis</i> .....	32
3.3.7	<i>In vitro Tube-forming Assay</i> .....	32
3.3.8	<i>Chemotactic Attraction</i> .....	33
3.3.9	<i>Glucose Stress</i> .....	33
3.4	<i>In vivo Study</i> .....	34
3.4.1	<i>Diabetic Mouse Model</i> .....	34
3.4.2	<i>EPO Treatment</i> .....	34
3.4.3	<i>Transplantation and EPO Treatment</i> .....	34
3.4.4	<i>RNA Extraction and cDNA Synthesis</i> .....	35
3.4.5	<i>Gene Expression Study</i> .....	35
3.4.6	<i>Tissue Procurement for Histological Studies</i> .....	36
3.4.7	<i>Tunel Assay</i> .....	36
3.4.8	<i>Immunostaining for eNOS</i> .....	37
3.4.9	<i>Detection of Stem cells in Left Ventricular Tissue</i> .....	37
3.4.9.1	<i>Sirius Red Staining</i> .....	37
3.4.9.2	<i>Millar Analysis</i> .....	38

	3.5	Statistical Analysis.....	38
4.		RESULTS.....	39—59
	4.1	<i>In vitro</i> Studies.....	39
	4.1.1	<i>Characterization of MSCs</i> .....	39
	4.1.2	<i>Stimulation of Cell Proliferation in Preconditioned Diabetic MSCs</i> .....	40
	4.1.3	<i>Gene Expression Profiling of MSCs</i> .....	42
	4.1.4	<i>Increased SOD Activity in Preconditioned MSCs</i> .....	44
	4.1.5	<i>Effect of IGF-1 and FGF-2 Preconditioning on Apoptosis</i>	45
	4.1.6	<i>Chemotactic Ability of Preconditioned Diabetic MSCs</i>	46
	4.1.7	<i>In vitro tube-forming ability in diabetic MSCs</i> .....	47
	4.1.8	<i>Real-time PCR gene Expression after Glucose Stress</i>	49
	4.2	<i>In vivo</i> Studies.....	50
	4.2.1	<i>Effect of EPO treatment on Gene expression of Diabetic Heart</i> .....	50
	4.2.2	<i>Decreased Myocardial Cell Apoptosis</i> .....	51
	4.2.3	<i>Enhancement of eNOS Expression</i> .....	52
	4.3	Transplantation Studies.....	54
	4.3.1	<i>Homing of MSCs</i> .....	54
	4.3.2	<i>Reduction in Tissue Fibrosis</i> .....	56
	4.3.3	<i>Hemodynamic Parameters</i> .....	58
5.		DISCUSSIONS.....	60—67
6.		REFERENCES.....	68—91